CORONA CORONA Remedies Q2 FY26 results (Jul–Sep 2025) and concall
CORONA Remedies Limited reported a strong Q2 and H1 FY26, with revenue growing 15.1% and 17% YoY respectively. Profitability also saw significant improvement, with Q2 EBITDA margin at 21.7% and H1 PAT growing 35.1% YoY. The company highlighted its recent acquisition of Bayer Zydus Pharma brands to bolster its women's healthcare and infertility portfolio, alongside plans for new therapeutic area entries and international expansion.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
Q2 FY26: revenue up 15.0%, net profit up 20.9% against the same quarter last year.
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|
| Revenue | 314 | 298 | 294 | 347 | 361 +15% |
| EBITDA | 67 | 69 | 54 | 70 | 78 +16% |
| Net profit | 43 | 45 | 31 | 46 | 52 +21% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
